AssetMark Inc
IMNM icon

AssetMark Inc’s Immunome IMNM Stock Holding History

AssetMark Inc’s Portfolio IMNM Stock Details IMNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$99.2K Buy
4,535
+1,442
+47% +$32.1K ﹤0.01% 1543
2025
Q4 		$66.4K Sell
3,093
-271
-8% -$4.76K ﹤0.01% 1618
2025
Q3 		$39.4K Buy
+3,364
New +$33.5K ﹤0.01% 1713

Other funds holding IMNM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return

AssetMark Inc's IMNM Position: Q1 2026 in Review

AssetMark Inc increased its Immunome (IMNM) stake by 47% in Q1 2026, buying an estimated $32.1K and bringing the position to 4,535 shares worth $99.2K. The position accounts for ﹤0.01% of the portfolio, ranked #1543.

AssetMark Inc first reported a position in IMNM in Q3 2025 and has held it in 3 quarters since. 200 funds tracked by Wall St. Rank hold IMNM as of Q1 2026.

  • AssetMark Inc held 4,535 shares of Immunome worth $99.2K as of Q1 2026.
  • AssetMark Inc bought 1,442 Immunome shares in Q1 2026, an estimated $32.1K.
  • Immunome made up ﹤0.01% of AssetMark Inc's portfolio in Q1 2026, its #1543 holding.
  • AssetMark Inc first reported a position in Immunome in Q3 2025 and has held it in 3 quarters since.
  • 200 funds tracked by Wall St. Rank held Immunome as of Q1 2026.

Based on AssetMark Inc's 13F filing for Q1 2026, filed 6 May 2026.